Trial Profile
A Randomized, Open, Three-dose (100 mg, 200 mg and 300 mg) Duplicate Bifunctional Crossover and Fixed 200mg Continuous Dose Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs Ravidasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Ascletis
- 12 Jul 2021 Results from two studies NCT03430830 and NCT03288636 assessing Pharmacokinetics, safety and tolerability of ravidasvir, with and without danoprevir/ritonavir, in healthy subjects published in the Antimicrobial Agents and Chemotherapy
- 27 Jun 2018 Status changed from recruiting to completed.
- 16 Feb 2018 New trial record